Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases

Nat Rev Nephrol. 2021 Nov;17(11):765-781. doi: 10.1038/s41581-021-00447-x. Epub 2021 Jul 1.

Abstract

Targeting the collecting duct water channel aquaporin 2 (AQP2) to the plasma membrane is essential for the maintenance of mammalian water homeostasis. The vasopressin V2 receptor (V2R), which is a GS protein-coupled receptor that increases intracellular cAMP levels, has a major role in this targeting process. Although a rise in cAMP levels and activation of protein kinase A are involved in facilitating the actions of V2R, studies in knockout mice and cell models have suggested that cAMP signalling pathways are not an absolute requirement for V2R-mediated AQP2 trafficking to the plasma membrane. In addition, although AQP2 phosphorylation is a known prerequisite for V2R-mediated plasma membrane targeting, none of the known AQP2 phosphorylation events appears to be rate-limiting in this process, which suggests the involvement of other factors; cytoskeletal remodelling has also been implicated. Notably, several regulatory processes and signalling pathways involved in AQP2 trafficking also have a role in the pathophysiology of autosomal dominant polycystic kidney disease, although the role of AQP2 in cyst progression is unknown. Here, we highlight advances in the field of AQP2 regulation that might be exploited for the treatment of water balance disorders and provide a rationale for targeting these pathways in autosomal dominant polycystic kidney disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • A Kinase Anchor Proteins / metabolism
  • Antidiuretic Hormone Receptor Antagonists / therapeutic use
  • Aquaporin 2 / metabolism*
  • Cell Membrane / metabolism
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism
  • Fluconazole
  • Humans
  • Kidney Tubules, Collecting / metabolism*
  • Polycystic Kidney, Autosomal Dominant / drug therapy
  • Polycystic Kidney, Autosomal Dominant / metabolism*
  • Protein Transport
  • Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors
  • Proto-Oncogene Proteins pp60(c-src) / metabolism
  • Receptors, Vasopressin / metabolism
  • Signal Transduction
  • Tolvaptan / therapeutic use
  • Water / metabolism*
  • Water-Electrolyte Balance / physiology*
  • Wnt-5a Protein / metabolism

Substances

  • A Kinase Anchor Proteins
  • Antidiuretic Hormone Receptor Antagonists
  • Aquaporin 2
  • Receptors, Vasopressin
  • Wnt-5a Protein
  • Water
  • Tolvaptan
  • Fluconazole
  • Cyclic AMP
  • ErbB Receptors
  • Proto-Oncogene Proteins pp60(c-src)
  • Cyclic AMP-Dependent Protein Kinases